PMID: 1189495Aug 1, 1975Paper

[Problems in the use of cardiac glycosides in ischemic heart disease].

Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete
D Modersohn, W Urbaszek

Abstract

With the help of instances from literature and own experimental and clinical experiences is described that a schematic digitalisation in ischaemic heart diseases is not worth being advocated scientifically. Heart glycosides are indicated especially then, when a heart insufficiency stands in the foreground. In the acute phase of infarction, without manifest heart insufficiency, however, in individual cases they can deteriorate the myocardial oxygen balance and thus the clinical course. In myocardial infarction with severe heart insufficiency up to the cardiogenic shock all therapeutic possibilities should be utilized; to this belongs also the application of glycosides. As a rule in cardiogenic shock after myocardial infarction glycosides have no sufficient measurable influence on haemodynamics. Heart glycosides together with an individually adapted kinetotherapy are of importance for the metaphylaxis in patients with infarction.

Related Concepts

Related Feeds

Cardiac Glycosides

Cardiac glycosides are a diverse family of naturally derived compounds that bind to and inhibit na+/k+-atpase. Discover the latest research on cardiac glycosides heres.

Cardiogenic Shock

Cardiogenic shock is a devastating consequence of acute myocardial infarction and is associated with an extremely high mortality. Here is the latest research.